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OBJECTIVE: The aim of this study was to compare the
costs and clinical consequences of olopatadine, a new
topical chemical entity with a dual mechanism of action
(anti-histamine and mast cell stabilizer) to those of topi-
cal cromolyn sodium (CS) in the treatment of seasonal al-
lergic conjunctivitis in Belgium, France, Germany, Neth-
erlands, Norway, Portugal and Sweden.
METHODS: A randomized, controlled, double-blind,
multi-country clinical trial compared the efficacy and
safety of olopatidine 0.1% bid and cromolyn sodium 2%
qid. An economic comparison of first line and first-line
failure treatments with olopatadine versus CS was mod-
eled using clinical trial results and a standard cost ap-
proach. A societal perspective was adopted. Cost of fail-
ure was established from Pinto (2001).
RESULTS: A total of 185 patients (91 olopatadine, 94
CS) presenting with SAC were treated over 42 days. At
day 42, olopatadine-treated patients had lower itching
(P  0.05) and redness (P  0.05) scores. The first-line,
treatment-failure rate was 12.5% less (P  0.02) in olo-
patadine-treated patients. Olopatadine patients had a 1.6
greater chance (P  .0001) of having a day without
symptoms, from day 1 to day 42. Olopatadine was as
safe as CS and well tolerated. According to Pinto, cost of
failure varied across countries from €48 to €72. Savings
per episode due to avoiding failures with olopatadine
were €7.00 in Belgium, €8.68 in France, €8.66 in Ger-
many, €6.12 in NL, €6.02 in Norway, €8.43 in Por-
tugal and €8.96 in Sweden. Sensitivity analyses were
conducted which confirmed the robustness of our find-
ings.
CONCLUSION: Based on results of a randomized clini-
cal trial, and resources and costs associated with failure
estimated from the literature, our model found that olo-
patadine is a cost-saving alternative to CS and offers
more clinical benefits to patients. Results were consistent
over all study countries.
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OBJECTIVE: The burden of sight impairment on govern-
ments’ welfare care budgets is large, and generally greater
than the associated health-care costs. The objective of
this study was to summarise and quantify the range of
welfare and social care benefits available to individuals
with sight impairment in nine countries.
METHODS: Local language literature searches, interviews
with representatives of benefit agencies, patient organisa-
tions, and clinical experts using a standard set of questions
adapted to local circumstances. ‘Typical’ cases were defined
according to age, family support and level of impairment.
RESULTS: Clinical criteria (e.g. visual acuity), functional
state or both may determine eligibility for benefits. Basic
monthly disability benefits reported, ranged from $159
(UK) to $479 (Germany). Countries with lower values
(UK, Sweden) provide a wider range of services free at
the point of use or higher benefits related to income or in-
ability to work. Higher levels of benefits in other coun-
tries are intended to cover direct purchase of services.
Benefits covering inability to work range from $135
(Spain) to $793 (Sweden), and for caring responsibilities
from $226 (UK) to $773 (France) per month. In most
countries the range of services/benefits for ‘typical’ cases
could be assessed.
CONCLUSION: Multinational studies assessing the eco-
nomic impact of sight impairment face problems due to
the fragmentation of payments and services across organ-
isations within each country, different financing struc-
tures and systems of payment/service organisations in dif-
ferent countries, and a lack of centrally held information
about numbers of claims in relation to the underlying
condition. It is necessary to tailor prospective studies to
the welfare systems in each country in order to capture
such costs and to ensure relevance of economic argu-
ments to the local environment. Decision-makers should
be encouraged the use of a wider economic perspective
when considering interventions preventing or delaying
the progress of visual impairment.
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OBJECTIVE: To compare the costs and consequences of
three strategies for correction of mild to moderate myo-
pia: laser in situ keratomileusis (Lasik), glasses and con-
tact lenses (CL).
METHODS: A Markov model compared the present value
of Lasik, glasses and CL. A structured questionnaire was
administered to 40 patients to collect resource utilization
data including direct medical and indirect non-medical
costs (transportation, time spent, hotel, spectacles, CL,
Lasik, cleaning stuff, visits to ophthalmologist, optome-
trist, optic centre, and adverse events linked to Lasik and
CL). Time horizon varied from 10 to 30 years with a 5%
discount rate. The economic perspective was that of the
Spanish society. Full sensitivity analyses were conducted.
